You are here: Industry Insights > Regenxbio

News List

Regenxbio, AbbVie close license and collaboration deal to develop RGX-314 Pharmaceutical-Business-Review
November 11, 2021
Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314.
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting prnewswire
May 17, 2021
REGENXBIO Inc. (Nasdaq: RGNX) today announced a safety update and additional positive interim data from the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also kn
Objective Acuity announces successful pilot study in children with CLN2 Batten disease prnasia
May 11, 2021
Objective Acuity today announced the completion of a pilot study using OAL's threshold visual acuity test for young children diagnosed with late-infantile neuronal ceroid lipofuscinosis Type 2 (CLN2 disease), a form of Batten disease.
REGENXBIO Doses First Patient in RGX-314 Trial for Diabetic Retinopathy americanpharmaceuticalreview
December 31, 2020
REGENXBIO announced the first patient has been dosed in ALTITUDE, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR).
REGENXBIO Doses First Patient in RGX-111 Trial for Mucopolysaccharidosis Type I Treatment americanpharmaceuticalreview
December 16, 2020
REGENXBIO announced the first patient has been dosed in the Phase I/II trial of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I).
REGENXBIO Achieves $80M Novartis Milestone contractpharma
October 29, 2020
Zolgensma, which leverages REGENXBIO's NAV AAV9 vector, reaches $1 billion in sales.
REGENXBIO Announces Dosing of First Patient in Trial for Wet AMD Using Suprachoroidal Delivery americanpharmaceuticalreview
September 14, 2020
REGENXBIO announced the first patient has been dosed in the AAVIATE trial, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration (wet AMD).
Regenxbio Announces FDA Clearance of IND for Trial of Diabetic Retinopathy Treatment americanpharmaceuticalreview
August 26, 2020
Regenxbio announced the clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR).
Regenxbio, Neurimmune to Develop Antibodies for Neurodegenerative Disease Treatment contractpharma
July 26, 2019
Potential to deliver sustained levels of therapeutic human antibodies to the brain with AAV vectors.
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease pharmafocusasia
November 26, 2018
REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform....

Previous page 1 2 Next page